Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rivaroxaban for acute portal, mesenteric, and splenic vein thrombosis
NL-OMON48974Phase 2Not yet recruiting
- Sponsor
- University of Insubria
- Start
- Sep 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rivaroxaban in splanchnic vein thrombosis, portal vein thrombosis (PVT), Mesenteric venous thrombosis (MVT) and 1 more, sponsored by University of Insubria. Primary endpoint: Major bleeding. Planned start Sep 2019; status: not yet recruiting.
02
Drugs
rivaroxaban
03
Conditions
splanchnic vein thrombosisportal vein thrombosis (PVT)Mesenteric venous thrombosis (MVT)splenic vein thrombosis (SVT)
Beyond the preview
Go deeper on NL-OMON48974.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON48974.